Third-line therapy for metastatic colorectal cancer.

BACKGROUND: The past years' therapy for colorectal cancer has evolved rapidly with the introduction of novel cytotoxic agents such as irinotecan, capecitabine and oxaliplatin. Further advances have been achieved with the integration of targeted agents such as bevacizumab, cetuximab and recently, panitumumab. As a result, third-line treatment is now a necessary step in the optimal treatment of patients with metastatic colorectal cancer (MCRC). MATERIALS AND METHODS: We conducted a literature review of English language publications on third-line therapy for MCRC from January 2000 to April 2007. Data on median overall survival (mOS), median time to progression (mTTP) and response rate were recorded. RESULTS: We found 27 articles and 22 abstracts to fulfil the criteria. Patients who received regimens containing oxaliplatin and infusional 5-fluorouracil (5-FU) demonstrated mTTP up to 7 months and a mOS of 16 months. With irinotecan and 5-FU, mOS around 8 months were reported and with cetuximab combined with irinotecan, the highest mOS was 9.8 months. CONCLUSION: Third-line therapy in advanced colorectal cancer may improve mOS for patients with MCRC. Therefore, randomized studies should be conducted in the future.

Enhancement of Y-maze learning by piracetam, 2-thio-1-pyrrolidine-acetamide and 2-thio-1-pyrrolidine-thio-acetamide in rats.

Learning of rats given either piracetam, 2-thio-1-pyrrolidine-acetamide (thioacet) or 2-thio-1-pyrrolidine-thio-acetamide (thiothio) was studied in order to investigate nootropic effects of the compounds. Learning ability was measured using a Y-maze with water reward for the correct choice in a black-white discrimination task. Thioacet and thiothio enhanced learning ability of the rats at doses that were 2.5-10 times lower than those required for obtaining nootropic effects of piracetam. Thus the thio-derivatives of piracetam might be of value for studying mechanisms of action of nootropic drugs.